MedTrace Logo

Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

NCT05369013 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 188

Last updated 2022-05-17

No results posted yet for this study

Summary

Non-interventional observational prospective follow-up study of cohorts of patients with Previous diagnosis of Osteoporosis with high risk of fractures, with/without previous fractures and treatment with bone formers (biosimilar or original Teriparatide), who meet all the inclusion criteria and exclusion, with prior information and signing of prior informed consent documents.

Conditions

Sponsors & Collaborators

  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    collaborator OTHER

  • Instituto Palacios

    collaborator OTHER

  • Complexo Hospitalario de Ourense

    collaborator OTHER

  • Hospital Universitario Central de Asturias

    collaborator OTHER

  • Parc Taulí Hospital Universitari

    collaborator OTHER

  • Hospital Universitario Fundación Jiménez Díaz

    collaborator OTHER

  • Hospital Universitario Infanta Leonor

    collaborator OTHER

  • Hospital Universitario Virgen Macarena

    collaborator OTHER

  • Hospital d´Igualada

    collaborator UNKNOWN

  • Alpha Bioresearch S.L.

    collaborator OTHER

  • STADA, Spain

    lead OTHER

Principal Investigators

  • Santiago Palacios · Instituto Palacios de la Salud de la Mujer. Presidente FHOEMO

  • Jose Luis Neyro · Hospital Universitario Cruces. Embajador FHOEMO

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2023-12-30
Completion
2024-04-14

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369013 on ClinicalTrials.gov